A patient with type 2 diabetes mellitus has a prescription for a change in oral antidiabetic agents from glipizide to acarbose. The patient asks the nurse why there is no need to be worried about the new drug causing hypoglycemia. What is the nurse's best answer?

Because your pancreatic function is improving, it does not need as much stimulation, so acarbose is not as powerful as glipizide.

Glipizide stimulates your pancreas to secrete insulin, increasing your risk for hypoglycemia. Acarbose does not stimulate insulin secretion; rather, it reduces your intestinal uptake of sugar.

Acarbose increases the cells' uptake of glucose without the need for insulin, so you cannot become hypoglycemic even if you miss a meal on the medication.

Glipizide is actually an oral form of insulin, and too much could make your blood sugar drop quickly. Acarbose reduces your blood sugar by suppressing pancreatic release of glucagon.

Advise the client to remain NPO for 24 hours before the CT scan